Angiogenesis in Chronic Obstructive Pulmonary Disease
DOI:
https://doi.org/10.12775/v10251-012-0050-6Keywords
angiogenesis, chronic obstructive pulmonary disease (COPD), pro- and antiangiogenic factors, vascular endothelial growth factor (VEGF), endothelial progenitor cells (EPCs)Abstract
Angiogenesis is a very important process that occurs in both physiological and pathological states. The new blood vessels formation is characteristic for cancers, ischemic diseases and inflammatory diseases. The process is controlled by factors that stimulate and inhibit neovascularization. The next stages of the neovascularization are known as well as the role of the extracellular matrix, cells and cytokines/factors growth modulating this process. The cells of the endothelium and proangiogenic factors are the most important. The endothelial progenitor cells (EPCs), which origin from bone marrow, are the cells involved in angiogenesis. VEGF is the most important factor of the first stages of new blood vessels formation; it is responsible for EPCs recruitment from bone marrow and their collecting in ischemic tissue.
Many researches that determine pathogenetic factors of the chronic obstructive pulmonary disease as its aim are conducted because of the frequency of appearing of this disease. The attempts to get to know the vascularization in COPD pathogenesis are made; however, published results may be ambiguous. More studies are needed for the explanation of the angiogenesis mechanism. Understanding it could be helpful in preparing more effective COPD therapy.
References
Zielonka T.M. Angiogeneza - część I. Mechanizm powstawania nowych naczyń krwionośnych. Alerg. Astma Immunol. 2003; 8(4): 169 - 174
Zielonka T.M. Angiogeneza - część II. Czynniki modulujące proces powstawania nowych naczyń krwionośnych. Alerg. Astma Immunol. 2004; 9(1), 25 - 31
Mannino DM., Buist AS. Global burden of COPD: risk factors, prevalence and future trends. Lancet 2007; 370: 765 - 73
Krasnowska M., Nittner - Marszalska M., Krasnowski R i wsp. Endotelina, czynnik von Willebranda i komórki śródbłonka we krwi obwodowej chorych na POChP. Alerg. Astma Immunol. 2001; 6(4):195 - 199
Mizia - Malarz A., Sobol G., Woś H. Angiogeneza w przewlekłych schorzeniach zapalnych i nowotworowych. Pol. Merk. Lek. 2008; 24: 141 - 185
Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 2004; 25: 581 - 611 [http://dx.doi.org/10.1210/er.2003-0027]
Browder T., Folkman J. The hemostatic system as a regulator of angiogenesis. J. Biol. Chem. 2000; 275: 1521 - 1524
Kanazawa H. Role of VEGF in the pathogenesis of chronic obstructive pulmonary disease. Med. Sci. Monit. 2007; 13: 189 - 195
Kluz J., Adamiec R. Circulating endothelial cells in inflammatory vascular disordes. Adv. Clin. Exp. Med. 2007, 16 (1): 95 - 104
Skóra J., Biegus J., Pupka A., et al. Molecular basics of angiogenesis. Postępy Hig. Med. Dośw. 2006, 60: 410 - 415
Folkman J. Angiogenesis in cancer vascular rheumatoid arthritis and other diseases. Nat. Med. 1995, 1: 27 - 30
Światowa strategia rozpoznawania, leczenia i prewencji przewlekłej obturacyjnej choroby płuc. Aktualizacja 2006. Med. Prakt. 2/2007 (wydanie specjalne)
Jeffery P.K. Remodeling in asthma and chronic obstructive lung disease. Am. J. Respir. Crit. Care. Med. 2001; 164: 28 - 38
Mróz R.M., Szulakowski P., Pierzchała W. Patogeneza przewlekłej obturacyjnej choroby płuc. Część I. Podłoże komórkowe. Wiad. Lek. 2006; 59 (1-2): 92 -96
Chung K.F., Adcock J.M. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur. Respir. J. 2008; 31: 1334 - 1356 [http://dx.doi.org/10.1183/09031936.00018908]
Ho C.L., Shen L.F., Li C.Y. Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non- Hodgkin lymphoma. Ann. Diagn. Pathol. 2003; 7: 1 - 8 [http://dx.doi.org/10.1053/adpa.2003.50000]
Poręba M., Jaźwiec B., Kuliczkowski K., i wsp. Krążące komórki śródbłonka, prekursory śródbłonka oraz stężenie VEGF i bFGF u chorych na ostre białaczki, chłoniaki i szpiczaki. Pol. Arch. Med. Wewn. 2005; 90: 27 - 34
Carmeliet P. Angiogenesic in health and disease. Nat. Med. 2003; 9: 653 - 660 [http://dx.doi.org/10.1038/nm0603-653]
Rovina N., Papapetropoulos A., Kollintza A., et al. VEGF: An angiogenic factor reflecting airway inflammation in healthy smokers and in patients with bronchitis type of COPD? Respir. Res. 2007; 8: 54 - 58
Kasahara Y., Rubin M.T., Cool C.D., et al. Expression of 15-lipoxygenase and evidence for apoptosis in the lungs from patients with COPD. 2000; 117 (5): 260 -266
Yasuda N., Gotoh K., Minatoguchi S., et al. An increase of soluble FAS, an inhibitor of apoptosis, associated with progression of COPD. Respir. Med. 1998; 92: 993 - 999 [http://dx.doi.org/10.1016/S0954-6111(98)90343-2]
Boussat S., Eddahibi S., Coste A., et al. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am. J. Physiol. Lung Cell Md. Physiol. 2000; 279: 371 - 383
Palange P., Testa U., Huertas A., et al. Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. Respir. Eur. J. 2006; 27 (3): 529 -541 [http://dx.doi.org/10.1183/09031936.06.00120604]
Sala E., Villena C., Rios A., et al. Abnormal levels of circulating endothelial progenitor cells during exacerbations of COPD. Lung. 2010; 188 (4): 331 -338
Higham M.A., Tetley T.D., Upton P.D., et al. IL-8 is elevated in bronchoalveolar lavage fluid (BALF) from chronic obstructive pulmonary disease (COPD) patients. Am. J. Respir. Crit. Care Med. 2000; 15: 281 -284
Pepper M.S., Mandriota S. J. Vassali J.D. Angiogenesis- regulating cytokines: activities and interactions. Curr Topics Microbiol. Immun 1996; 213: 31 - 67
Ge R.L., Kubo K., Yamamoto H., et al. Role of VEGF and TGF-βeta for vascular remodeling in emphysema. Am. J. Respir. Crit. Care Med. 1999; 159: 48 - 56
Downloads
Published
How to Cite
Issue
Section
Stats
Number of views and downloads: 461
Number of citations: 0
